Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materializ...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Ebi, Hiromichi, Faber, Anthony C, Engelman, Jeffrey A, Yano, Seiji
Formaat: Online Artikel Texto
Taal:English
Gepubliceerd in: BlackWell Publishing Ltd 2014
Onderwerpen:
Review Article
Online toegang:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830/
https://www.ncbi.nlm.nih.gov/pubmed/24612015
http://dx.doi.org/10.1111/cas.12383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830/
https://www.ncbi.nlm.nih.gov/pubmed/24612015
http://dx.doi.org/10.1111/cas.12383

Gelijkaardige items